AVO.L Share Price (AVO)

Strange that nobody was interested in buying AVO from the administrators.

I gave up believing that these clowns would ever succeed years ago, and sold out, but I did believe in the technology. If LIGHT is half as good as AVO claimed, I thought it would have been snapped up by a rival.

The post when I bought them below 30th June 2022 in ISA , it appears my buy after a placing .

( D ) buying unavailable maybe .

Hope so in hindsight .

It appears no one was interested in buying it out of administration

Hilco Valuation Services Europe is an industry-leading, full service asset valuation, advisory and sales practice that puts our clients at the heart of everything we do.

Advanced Oncotherapy PLC –

In Administration

Offer Deadline:

Overview

An opportunity has arisen to acquire the business and assets of Advanced Oncotherapy PLC, a pioneering UK-based company active in the field of proton particle therapy. This advanced radiation-based approach to cancer treatment offers superior precision and fewer side effects compared to X-ray machines.

Established in 2006, and with technology initially nurtured at CERN, the company has designed a system (“LIGHT”) that provides the most precise and fastest proton beam for cancer treatment while offering significant cost savings for payers.

Due to LIGHT’s modularity, which allows for easier and cheaper installation into existing buildings, the equipment can be leased, accelerating market adoption and replicating the success of other medical equipment like MRI scanners. This results in significantly reduced upfront costs for any future operators.

In focus

LIGHT has been designed to deliver proton therapy, a more targeted radiation than X-rays, at a price closer to conventional radiation treatments.

The innovative technology promises better quality treatment with pinpoint accuracy compared to existing technologies.

The company has achieved a significant milestone by generating a high-energy proton beam, enabling LIGHT to treat tumours at depths of up to 32 cm and considerably de-risking the business plan. Following this achievement, the company will be integrating the linear accelerator with the equipment in the treatment room (such as the patient couch or the scanner used to locate the tumour), calibrating the imaging equipment, and obtaining regulatory approvals.

The technology aims to create synergies with other approaches, such as immunotherapy, and has the potential to treat non-cancerous disorders.

The company is currently installing a linear system into a Grade II listed townhouse in central London with construction costs of £10 million, compared to UCLH’s circular system, which cost approximately £190 million.

Another AIM gone bust complete loss .

Further to our previous communication on 5th November 2024, we received confirmation that Advanced Oncotherapy Plc (Advanced) shares have been declared void and worthless.

We have therefore removed the Advanced shares from your account.

If we receive a distribution from the Company, we'll let you know at that time. However, there can be no certainty that such a distribution will be made.

Nothing to see here for shareholders, when it looks like HMRC won’t be paid, it says it all

Noted in reading the detail that less than 1% of potential patients could be treated due to high costs it shows it as a well intended pipe dream, the science worked but was completely unaffordable